Citadel Advisors’s VanEck Biotech ETF BBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.79M | Buy |
+9,514
| New | +$1.83M | ﹤0.01% | 6318 |
|
|
2025
Q4 | – | Sell |
-2,853
| Closed | -$473K | – | 12663 |
|
|
2025
Q3 | $473K | Sell |
2,853
-5,307
| -65% | -$865K | ﹤0.01% | 9268 |
|
|
2025
Q2 | $1.25M | Buy |
8,160
+5,638
| +224% | +$840K | ﹤0.01% | 6610 |
|
|
2025
Q1 | $397K | Sell |
2,522
-3,254
| -56% | -$528K | ﹤0.01% | 8989 |
|
|
2024
Q4 | $907K | Sell |
5,776
-16,038
| -74% | -$2.7M | ﹤0.01% | 7246 |
|
|
2024
Q3 | $3.87M | Buy |
+21,814
| New | +$3.87M | ﹤0.01% | 4360 |
|
|
2024
Q1 | – | Sell |
-4,317
| Closed | -$714K | – | 14549 |
|
|
2023
Q4 | $714K | Buy |
4,317
+1,621
| +60% | +$250K | ﹤0.01% | 7358 |
|
|
2023
Q3 | $420K | Sell |
2,696
-17,542
| -87% | -$2.8M | ﹤0.01% | 8450 |
|
|
2023
Q2 | $3.16M | Buy |
20,238
+14,093
| +229% | +$2.25M | ﹤0.01% | 4374 |
|
|
2023
Q1 | $996K | Buy |
+6,145
| New | +$994K | ﹤0.01% | 6790 |
|
|
2022
Q4 | – | Sell |
-11,834
| Closed | -$1.67M | – | 14865 |
|
|
2022
Q3 | $1.67M | Buy |
+11,834
| New | +$1.79M | ﹤0.01% | 5941 |
|
|
2022
Q2 | – | Sell |
-5,109
| Closed | -$828K | – | 12863 |
|
|
2022
Q1 | $828K | Sell |
5,109
-6,948
| -58% | -$1.13M | ﹤0.01% | 8140 |
|
|
2021
Q4 | $2.28M | Buy |
12,057
+2,710
| +29% | +$523K | ﹤0.01% | 5941 |
|
|
2021
Q3 | $1.89M | Buy |
9,347
+2,614
| +39% | +$549K | ﹤0.01% | 6508 |
|
|
2021
Q2 | $1.36M | Sell |
6,733
-11,021
| -62% | -$2.05M | ﹤0.01% | 7555 |
|
|
2021
Q1 | $3.12M | Sell |
17,754
-5,395
| -23% | -$976K | ﹤0.01% | 5355 |
|
|
2020
Q4 | $3.92M | Buy |
23,149
+16,114
| +229% | +$2.65M | ﹤0.01% | 4097 |
|
|
2020
Q3 | $1.14M | Sell |
7,035
-9,657
| -58% | -$1.57M | ﹤0.01% | 5798 |
|
|
2020
Q2 | $2.72M | Buy |
16,692
+3,137
| +23% | +$477K | ﹤0.01% | 4032 |
|
|
2020
Q1 | $1.74M | Buy |
+13,555
| New | +$1.83M | ﹤0.01% | 4381 |
|
|
2019
Q4 | – | Sell |
-39,034
| Closed | -$4.61M | – | 9101 |
|
|
2019
Q3 | $4.61M | Buy |
39,034
+698
| +2% | +$86.8K | ﹤0.01% | 3224 |
|
|
2019
Q2 | $4.96M | Sell |
38,336
-8,728
| -19% | -$1.08M | ﹤0.01% | 3094 |
|
|
2019
Q1 | $6.05M | Buy |
47,064
+25,547
| +119% | +$3.23M | ﹤0.01% | 2731 |
|
|
2018
Q4 | $2.39M | Buy |
21,517
+17,806
| +480% | +$2.15M | ﹤0.01% | 3869 |
|
|
2018
Q3 | $506K | Buy |
+3,711
| New | +$483K | ﹤0.01% | 6667 |
|
|
2016
Q4 | – | Sell |
-6,295
| Closed | -$725K | – | 7248 |
|
|
2016
Q3 | $725K | Sell |
6,295
-5,371
| -46% | -$612K | ﹤0.01% | 4283 |
|
|
2016
Q2 | $1.2M | Sell |
11,666
-23,273
| -67% | -$2.48M | ﹤0.01% | 3352 |
|
|
2016
Q1 | $3.62M | Sell |
34,939
-5,074
| -13% | -$529K | ﹤0.01% | 2075 |
|
|
2015
Q4 | $5.08M | Buy |
40,013
+31,599
| +376% | +$3.87M | 0.01% | 1807 |
|
|
2015
Q3 | $962K | Buy |
8,414
+393
| +5% | +$52K | ﹤0.01% | 3877 |
|
|
2015
Q2 | $1.08M | Sell |
8,021
-726
| -8% | -$96.5K | ﹤0.01% | 3859 |
|
|
2015
Q1 | $1.13M | Buy |
8,747
+6,031
| +222% | +$758K | ﹤0.01% | 3768 |
|
|
2014
Q4 | $313K | Buy |
+2,716
| New | +$306K | ﹤0.01% | 5365 |
|
|
2014
Q3 | – | Sell |
-5,172
| Closed | -$493K | – | 8107 |
|
|
2014
Q2 | $493K | Buy |
+5,172
| New | +$464K | ﹤0.01% | 4411 |
|
Other funds holding BBH
MIM
CCA
BFG
Citadel Advisors's BBH Position: Q1 2026 in Review
Citadel Advisors opened a new position in VanEck Biotech ETF (BBH) in Q1 2026: 9,514 shares worth $1.79M. The stake represents ﹤0.01% of the portfolio and ranks #6318 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BBH as recently as Q3 2025.
Citadel Advisors first reported a position in BBH in Q2 2014 and has held it in 34 quarters since. The position peaked at $6.05M in Q1 2019. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.
- Citadel Advisors held 9,514 shares of VanEck Biotech ETF worth $1.79M as of Q1 2026.
- VanEck Biotech ETF was a new Citadel Advisors position in Q1 2026.
- VanEck Biotech ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6318 holding.
- Citadel Advisors first reported a position in VanEck Biotech ETF in Q2 2014 and has held it in 34 quarters since.
- Citadel Advisors's VanEck Biotech ETF position peaked at $6.05M in Q1 2019.
- 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.